علاج تجلط الأوردة العميقة في الطرف العلوي مع وجود قسطرة وريدية مركزية موضوعة أو نظام منفذ

References

DOI: 10.1161/circulationaha.111.051276

1. Catheter-associated UEDVT accounts for the vast majority of secondary forms, resulting mainly from indwelling central venous lines or port systems and less frequently from pacemaker or defibrillator leads.
2. In patients with catheter-associated UEDVT (with or without cancer), anticoagulation therapy can be discontinued after 3 months if the central venous catheter is removed; if the catheter is not removed, anticoagulation therapy should be continued as long as the catheter remains.
3. If a catheter is occluded, an attempt to restore patency can be performed by instillation of thrombolytics, with 1 or 2 doses of 2 mg recombinant tissue-type plasminogen activator.
4. The optimal timing of catheter removal has not been evaluated, but it is usually appropriate to remove the catheter after 3 to 5 days of anticoagulant therapy.